Weight Change and the Association with Adherence and Persistence to Diabetes Therapy: A Narrative Review

References

• Leitner DR, Frühbeck G, Yumuk V, et al. Obesity and type 2 diabetes: two disease with a need for combined treatment strategies – EASO can lead the way. Obes Facts. 2017;10(5):483–492. doi:10.1159/000480525
   PubMed Web of Science ®Google Scholar
• Gatineau M, Hancock C, Holman N, et al. Public Health England. Adult obesity and type 2 diabetes; 2014. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/338934/Adult_obesity_and_type_2_diabetes_.pdf. Accessed March 18, 2021.
   Google Scholar
• Centers for Disease Control and Prevention. National diabetes statistics report; 2020. Available from: https://www.cdc.gov/diabetes/library/features/diabetes-stat-report.html. Accessed November 15, 2021. 18, 2021.
   Google Scholar
• Salinero-Fort MA, San Andrés-Rebollo FJ, Gómez-Campelo P, et al. Body mass index and all-cause mortality among type 2 diabetes mellitus patients: findings from the 5-year follow-up of the MADIABETES cohort. Eur J Intern Med. 2017;43:46–52. doi:10.1016/j.ejim.2017.06.021
   PubMed Web of Science ®Google Scholar
• Bae JP, Lage MJ, Mo D, et al. Obesity and glycemic control in patients with diabetes mellitus: analysis of physician electronic health records in the US from 2009–2011. J Diabetes Complications. 2016;30(12):212–220. doi:10.1016/j.jdiacomp.2015.11.016
   PubMed Web of Science ®Google Scholar
• Boye KS, Lage MJ, Thieu V, et al. Obesity and glycemic control among people with type 2 diabetes in the United States: a retrospective cohort study using insurance claims data. J Diabetes Complications. 2021;35(9):107975. doi:10.1016/j.jdiacomp.2021.107975
   PubMed Web of Science ®Google Scholar
• Weng W, Tian Y, Kimball ES, et al. Treatment patterns and clinical characteristics of patients with type 2 diabetes mellitus according to body mass index: findings from an electronic medical records database. BMJ Open Diabetes Res Care. 2017;5(1):e000382. doi:10.1136/bmjdrc-2016-000382
   PubMed Web of Science ®Google Scholar
• Gray N, Picone G, Sloan F, et al. The relationship between BMI and onset of diabetes mellitus and its complications. South Med J. 2015;108(1):29–36. doi:10.14423/SMJ.0000000000000214
   PubMed Web of Science ®Google Scholar
• Boye KS, Lage MJ, Terrell K. Healthcare outcomes for patients with type 2 diabetes with and without comorbid obesity. J Diabetes Complications. 2020;34(12):107730. doi:10.1016/j.jdiacomp.2020.107730
   PubMed Web of Science ®Google Scholar
• Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic review of scientific evidence from across the world in 2007–2017. Cardiovasc Diabetol. 2018;17(1):83. doi:10.1186/s12933-018-0728-6
   PubMed Web of Science ®Google Scholar
• Johnston SS, Ammann EM, Kashyap SR, et al. Body mass index and insulin as identifiers of high-cost patients with type 2 diabetes: a retrospective analysis of electronic health records linked to insurance claims data. Diabetes Obes Metab. 2019;21(6):1419–1428. doi:10.1111/dom.13671
   PubMed Web of Science ®Google Scholar
• Li Q, Blume SW, Huang JC, Hammer M, Graf TR. The economic burden of obesity by glycemic stage in the United States. PharmacoEconomics. 2015;33(7):735–748. doi:10.1007/s40273-014-0248-5
   PubMed Web of Science ®Google Scholar
• Meyers JL, Parasuraman S, Bell KF, et al. The high-cost, type 2 diabetes mellitus patient: an analysis of managed care administrative data. Arch Public Health. 2014;72(1):6. doi:10.1186/2049-3258-72-6
   PubMedGoogle Scholar
• American Diabetes Association (ADA). Obesity management for the treatment of type 2 diabetes. Standards of Medical Care in Diabetes – 2021. Diabetes Care. 2021;44(suppl1):S100–110. doi:10.2337/dc21-S008
   PubMed Web of Science ®Google Scholar
• Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669–2701. doi:10.2337/dci18-0033
   PubMed Web of Science ®Google Scholar
• Hurren KM, Dunham MW. Understanding the impact of commonly utilized, non-insulin, glucose-lowering drugs on body weight in patients with type 2 diabetes. Expert Opin Pharmacother. 2018;19(10):1087–1095. doi:10.1080/14656566.2018.1494727
   PubMed Web of Science ®Google Scholar
• Apovian CM, Okemah J, O’Neil PM. Body weight considerations in the management of type 2 diabetes. Adv Ther. 2019;36(1):44–58. doi:10.1007/s12325-018-0824-8
   PubMed Web of Science ®Google Scholar
• McGovern A, Tippu Z, Hinton W, et al. Comparison of medication adherence and persistence in type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2018;20(4):1040–1043. doi:10.1111/dom.13160
   PubMed Web of Science ®Google Scholar
• Weiss T, Carr RD, Pal S, et al. Real-world adherence and discontinuation of glucagon-like peptide-1 receptor agonists therapy in type 2 diabetes mellitus patients in the United States. Patient Prefer Adherence. 2020;14:2337–2345. doi:10.2147/PPA.S277676
   PubMed Web of Science ®Google Scholar
• Giorgino F, Penfornis A, Pechtner V, et al. Adherence to antihyperglycemic medications and glucagon-like peptide-1-receptor agonists in type 2 diabetes: clinical consequences and strategies for improvement. Patient Prefer Adherence. 2018;12:707–719. doi:10.2147/PPA.S151736
   PubMed Web of Science ®Google Scholar
• Kennedy-Martin T, Boye KS, Peng X. Cost of medication adherence and persistence in type 2 diabetes mellitus: a literature review. Patient Prefer Adherence. 2017;11:1103–1117. doi:10.2147/PPA.S136639
   PubMed Web of Science ®Google Scholar
• Dilla T, Costi M, Boye KS, et al. [The impact of obesity in the management and evolution of diabetes mellitus]. Rev Clin Esp. 2008;208(9):437–443. doi:10.1157/13127604
   PubMed Web of Science ®Google Scholar
• Polonsky WH, Henry RR. Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors. Patient Prefer Adherence. 2016;10:1299–1307. doi:10.2147/PPA.S106821
   PubMed Web of Science ®Google Scholar
• Vrijens B, De Geest S, Hughes DA, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012;73(5):691–705. doi:10.1111/j.1365-2125.2012.04167.x
   PubMed Web of Science ®Google Scholar
• Russell-Jones D, Pouwer F, Khunti K. Identification of barriers to insulin therapy and approaches to overcome them. Diabetes Obes Metab. 2018;20(3):488–496. doi:10.1111/dom.13132
   PubMed Web of Science ®Google Scholar
• Ng CJ, Lai PS, Lee YK, et al. Barriers and facilitators to starting insulin in patients with type 2 diabetes: a systematic review. Int J Clin Pract. 2015;69(10):1050–1070. doi:10.1111/ijcp.12691
   PubMed Web of Science ®Google Scholar
• Berard L, Antonishyn N, Arcudi K, et al. Insulin matters: a practical approach to basal insulin management in type 2 diabetes. Diabetes Ther. 2018;9(2):501–519. doi:10.1007/s13300-018-0375-7
   PubMed Web of Science ®Google Scholar
• Khan H, Lasker SS, Chowdhury TA. Prevalence and reasons for insulin refusal in Bangladeshi patients with poorly controlled Type 2 diabetes in East London. Diabet Med. 2008;25(9):1108–1111. doi:10.1111/j.1464-5491.2008.02538.x
   PubMed Web of Science ®Google Scholar
• Lakkis NA, Maalouf GJ, Mahmassani DM, Hamadeh GN. Insulin therapy attitudes and beliefs of physicians in Middle Eastern Arab countries. Fam Pract. 2013;30(5):560–567. doi:10.1093/fampra/cmt022
   PubMed Web of Science ®Google Scholar
• Nakar S, Yitzhaki G, Rosenberg R, Vinker S. Transition to insulin in Type 2 diabetes: family physicians’ misconception of patients’ fears contributes to existing barriers. J Diabetes Complications. 2007;21(4):220–226. doi:10.1016/j.jdiacomp.2006.02.004
   PubMed Web of Science ®Google Scholar
• Campbell MD, Babic D, Bolcina U, et al. High level of clinical inertia in insulin initiation in type 2 diabetes across Central and South-Eastern Europe: insights from SITIP study. Acta Diabetol. 2019;56:1045–1049. doi:10.1007/s00592-019-01346-1
   PubMed Web of Science ®Google Scholar
• Kalirai S, Ivanova JI, Perez-Nieves M, et al. Basal insulin initiation and maintenance in adults with type 2 diabetes mellitus in the United States. Diabetes Metab Syndr Obesity. 2020;13:1023–1033. doi:10.2147/DMSO.S237948
   PubMed Web of Science ®Google Scholar
• Peyrot M, Skovlund SE, Landgraf R. Epidemiology and correlates of weight worry in the multinational Diabetes Attitudes, Wishes and Needs study. Curr Med Res Opin. 2009;25(8):1985–1993. doi:10.1185/03007990903073654
   PubMed Web of Science ®Google Scholar
• Brod M, Lessard Alolga S, Meneghini L. Barriers to initiating insulin in type 2 diabetes patients: development of a new patient education tool to address myths, misconceptions and clinical realities. Patient. 2014;7(4):437–450. doi:10.1007/s40271-014-0068-x
   PubMedGoogle Scholar
• Lee YK, Lee PY, Ng CJ. A qualitative study on healthcare professionals’ perceived barriers to insulin initiation in a multi-ethnic population. BMC Fam Pract. 2012;13:28. doi:10.1186/1471-2296-13-28
   PubMed Web of Science ®Google Scholar
• Tan AM, Muthusamy L, Ng CC, Phoon KY, Ow JH, Tan NC. Initiation of insulin for type 2 diabetes mellitus patients: what are the issues? A qualitative study. Singapore Med J. 2011;52(11):801–809.
   PubMed Web of Science ®Google Scholar
• Carls GS, Tan R, Zhu JY, et al. Real-world weight change among patients treated with glucagon-like peptide-1 receptor agonist, dipeptidyl peptidase-4 inhibitor and sulfonylureas for type 2 diabetes and the influence of medication adherence. Obes Sci Pract. 2017;3(3):342–351. doi:10.1002/osp4.116
   PubMed Web of Science ®Google Scholar
• Gordon J, McEwan P, Idris I, et al. Treatment choice, medication adherence and glycemic efficacy in people with type 2 diabetes: a UK clinical practice database study. BMJ Open Diabetes Res Care. 2018;6(1):e000512. doi:10.1136/bmjdrc-2018-000512
   PubMed Web of Science ®Google Scholar
• Grandy S, Fox KM, Hardy E. Association of weight loss and medication adherence among adults with type 2 diabetes mellitus: SHIELD (Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes). Curr Ther Res Clin Exp. 2013;75:77–82. doi:10.1016/j.curtheres.2013.06.004
   PubMedGoogle Scholar
• McAdam-Marx C, Bellows BK, Unni S, et al. Determinants of glycaemic control in a practice setting: the role of weight loss and treatment adherence (the DELTA Study). Int J Clin Pract. 2014;68(11):1309–1317. doi:10.1111/ijcp.12502
   PubMed Web of Science ®Google Scholar
• McAdam-Marx C, Bellows BK, Unni S, et al. Impact of adherence and weight loss on glycemic control in patients with type 2 diabetes: cohort analyses of integrated medical record, pharmacy claims, and patient-reported data. J Manag Care Spec Pharm. 2014;20(7):691–700. doi:10.18553/jmcp.2014.20.7.691
   PubMed Web of Science ®Google Scholar
• Patel S, Abreu M, Tumyan A, et al. Effect of medication adherence on clinical outcomes in type 2 diabetes: analysis of the SIMPLE study. BMJ Open Diabetes Res Care. 2019;7(1):e000761. doi:10.1136/bmjdrc-2019-000761
   PubMed Web of Science ®Google Scholar
• Bell K, Parasuraman S, Shah M, et al. Economic implications of weight change in patients with type 2 diabetes mellitus. Am J Manag Care. 2014;20(8):e320–329.
   PubMed Web of Science ®Google Scholar
• Melzer-Cohen C, Chodick G, Husemoen LLN, et al. A retrospective database study of liraglutide persistence associated with glycemic and body weight control in patients with type 2 diabetes. Diabetes Ther. 2019;10(2):683–696. doi:10.1007/s13300-019-0583-9
   PubMed Web of Science ®Google Scholar
• Durden E, Liang M, Fowler R, Panton UH, Mocevic E. The effect of early response to GLP-1 RA therapy on long-term adherence and persistence among type 2 diabetes patients in the United States. J Manag Care Spec Pharm. 2019;25(6):669–680. doi:10.18553/jmcp.2019.18429
   PubMed Web of Science ®Google Scholar
• Fridman M, Lucas ME, Paprocki Y, et al. Impact of weight change in adults with type 2 diabetes mellitus: a literature review and critical analysis. Clinicoecon Outcomes Res. 2020;12:555–566. doi:10.2147/CEOR.S266873
   PubMed Web of Science ®Google Scholar
• Khunti K, Millar-Jones D. Clinical inertia to insulin initiation and intensification in the UK: a focused literature review. Prim Care Diabetes. 2017;11(1):3–12. doi:10.1016/j.pcd.2016.09.003
   PubMed Web of Science ®Google Scholar
• Psarou A, Cooper H, Wilding JPH. Patients’ perspectives of oral and injectable type 2 diabetes medicines, their body weight and medicine-taking behavior in the UK: a systematic review and meta-ethnography. Diabetes Ther. 2018;9(5):1791–1810. doi:10.1007/s13300-018-0490-5
   PubMed Web of Science ®Google Scholar
• de Climens AR, Pain E, Boss A, Shaunik A. Understanding reasons for treatment discontinuation, attitudes and education needs among people who discontinue type 2 diabetes treatment: results from an online patient survey in the USA and UK. Diabetes Ther. 2020;11(8):1873–1881. doi:10.1007/s13300-020-00843-9
   PubMed Web of Science ®Google Scholar
• Peyrot M, Perez-Nieves M, Ivanova J, et al. Correlates of basal insulin persistence among insulin-naïve people with type 2 diabetes: results from a multinational survey. Curr Med Res Opin. 2017;33(10):1843–1851. doi:10.1080/03007995.2017.1341868
   PubMed Web of Science ®Google Scholar
• Sikirica MV, Martin AA, Wood R, et al. Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes. Diabetes Metab Syndr Obes. 2017;10:403–412. doi:10.2147/DMSO.S141235
   PubMed Web of Science ®Google Scholar
• Wu J, Morrison F, Zhao Z, et al. Reasons for discontinuing insulin and factors associated with insulin discontinuation in patients with type 2 diabetes mellitus: a real-world evidence study. Clin Diabetes Endocrinol. 2021;7(1):1. doi:10.1186/s40842-020-00115-2
   PubMedGoogle Scholar
• Hauber AB, Mohamed AF, Johnson FR, et al. Treatment preferences and medication adherence of people with Type 2 diabetes using oral glucose-lowering agents. Diabet Med. 2009;26(4):416–424. doi:10.1111/j.1464-5491.2009.02696.x
   PubMed Web of Science ®Google Scholar
• Mohamed AF, Zhang J, Johnson FR, et al. Avoidance of weight gain is important for oral type 2 diabetes treatments in Sweden and Germany: patient preferences. Diabetes Metab. 2013;39(5):397–403. doi:10.1016/j.diabet.2013.06.001
   PubMedGoogle Scholar
• Morillas C, Feliciano R, Catalina PF, et al. Patients’ and physicians’ preferences for type 2 diabetes mellitus treatments in Spain and Portugal: a discrete choice experiment. Patient Prefer Adherence. 2015;9:1443–1458. doi:10.2147/PPA.S88022
   PubMed Web of Science ®Google Scholar
• Matza LS, Yurgin N, Boye KS, et al. Obese versus non-obese patients with type 2 diabetes: patient-reported outcomes and utility of weight change. Curr Med Res Opin. 2007;23(9):2051–2062. doi:10.1185/030079907X219454
   PubMed Web of Science ®Google Scholar
• Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger P-M. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabetic Med. 2012;29(5):682–689. doi:10.1111/j.1464-5491.2012.03605.x
   PubMed Web of Science ®Google Scholar
• Alatawi YM, Kavookjian J, Ekong G, Alrayees MM. The association between health beliefs and medication adherence among patients with type 2 diabetes. Res Social Adm Pharm. 2016;12(6):914–925. doi:10.1016/j.sapharm.2015.11.006
   PubMed Web of Science ®Google Scholar
• Farmer AJ, Rodgers LR, Lonergan M, et al. Adherence to oral glucose-lowering therapies and associations with 1-year HbA1c: a retrospective cohort analysis in a large primary care database. Diabetes Care. 2016;39(2):258–263. doi:10.2337/dc15-1194
   PubMed Web of Science ®Google Scholar
• Abu Hassan H, Tohid H, Mohd Amin R, Long Bidin MB, Muthupalaniappen L, Omar K. Factors influencing insulin acceptance among type 2 diabetes mellitus patients in a primary care clinic: a qualitative exploration. BMC Fam Pract. 2013;14:164. doi:10.1186/1471-2296-14-164
   PubMed Web of Science ®Google Scholar
• Parry O, Peel E, Douglas M, Lawton J. Issues of cause and control in patient accounts of Type 2 diabetes. Health Educ Res. 2006;21(1):97–107. doi:10.1093/her/cyh044
   PubMed Web of Science ®Google Scholar
• Phillips A. Experiences of patients with type 2 diabetes starting therapy. Nurse Stand. 2007;21(30):35–41. doi:10.7748/ns.21.23.35.s54
   Google Scholar
• Noakes H. Perceptions of black African and African-Caribbean people regarding insulin. J Diabetes Nurs. 2010;14:148–156.
   Google Scholar
• Ross SA, Dzida G, Vora J, et al. Impact of weight gain on outcomes in type 2 diabetes. Curr Med Res Opin. 2011;27(7):1431–1438. doi:10.1185/03007995.2011.585396
   PubMed Web of Science ®Google Scholar
• Crawford R, Glover L. The impact of pre-treatment weight-loss expectations on weight loss, weight regain, and attrition in people who are overweight and obese: a systematic review of the literature. Br J Health Psychol. 2012;17(3):609–630. doi:10.1111/j.2044-8287.2011.02059.x
   PubMed Web of Science ®Google Scholar
• Calugi S, Marchesini G, El Ghoch M, Gavasso I, Dalle Grave R. The influence of weight-loss expectations on weight loss and of weight-loss satisfaction on weight maintenance in severe obesity. J Acad Nutr Diet. 2017;117(1):32–38. doi:10.1016/j.jand.2016.09.001
   PubMed Web of Science ®Google Scholar
• Williamson DA, Bray GA, Ryan DH. Is 5% weight loss a satisfactory criterion to define clinically significant weight loss? Obesity. 2015;23(12):2319–2320. doi:10.1002/oby.21358
   PubMed Web of Science ®Google Scholar